Clarify Health, which offers a healthcare analytics service with data on 300M+ Americans, raises a $150M Series D, sources say at a $1.4B valuation
Michelle F Davis / Bloomberg :
Context & Ripple Effects
A year after its $115M Series C, which centered on social determinants of health data, Clarify Health has nearly doubled its raise size with a $150M Series D at a reported $1.4B valuation — the kind of step-up that marks the transition from analytics vendor to data platform.
The round lands in the middle of a funding wave for health-data infrastructure: HealthVerity raised $100M Series D for patient data management in mid-2021, Reveleer pulled $65M for payer analytics in December, and Reify Health's $220M Series D at $4.8B+ followed just weeks after this round — capital is consolidating around whoever holds the largest datasets.
First-order effects
- Clarify Health now has the balance sheet to scale an analytics service built on data covering 300M+ Americans, competing directly for payer, provider, and life-sciences analytics budgets.
- The $1.4B reported valuation puts Clarify in unicorn territory alongside peers like Collective Health, whose $1.5B post-money raise set the benchmark for health-data platforms.
Second-order effects
- Rivals holding comparable datasets — HealthVerity, Reveleer, Abacus Insights — face pressure to raise at similar scale or differentiate, since customers increasingly buy data breadth rather than point analytics tools.
- Pharma and insurance buyers gain a deeper pool of capitalized analytics vendors, strengthening their negotiating position on data licensing and contract pricing.
Third-order effects
- If the funding pattern holds, US health-data analytics consolidates around a handful of large-scale platforms, concentrating control over population-level health information in fewer hands — a structure likely to attract privacy and regulatory scrutiny as datasets like Clarify's 300M+ person coverage become standard infrastructure.
The trend: Healthcare is consolidating around scaled data platforms, with Series D mega-rounds determining which analytics vendors control population-level health data.